Wave Life Sci­ences to re­ceive $170M up­front in new part­ner­ship with GSK to de­vel­op a large num­ber of can­di­dates

Wave Life Sci­ences has picked up an­oth­er deal with a ma­jor phar­ma com­pa­ny.

The Mass­a­chu­setts-based biotech on Tues­day an­nounced it has en­tered a strate­gic col­lab­o­ra­tion with GSK to ad­vance oligonu­cleotide ther­a­peu­tics. This in­cludes mov­ing along Wave’s RNA edit­ing pro­gram that tar­gets al­pha-1 an­tit­rypsin de­fi­cien­cy, dubbed WVE-006, which af­fects both the lungs and liv­er with lim­it­ed treat­ment op­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER